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Abstract: Moroctocog alpha is a human B-domain deleted recombinant factor VIII (BDDrFVIII), which represents a new generation
of pure antihemophilic products. We describe here an optimized procedure for polyclonal anti-FVIII-antibody production with
the use of BDDrFVIII as an immunogen. The main immunochemical characteristics of the produced antibodies and their potential
biomedical applications are also reported. Rabbits were immunized with BDDrFVIII as an emulsion with Freund’s adjuvant or with
antigen immobilized in polyacrylamide gel (PAAG). Antibody titers in immune sera were assayed by enzyme-linked immunosorbent
assay (ELISA). IgG purification was performed by affine chromatography on protein A-sepharose. Immune sera and IgG were tested
by immunoblotting with the use of human plasma of healthy donors and people with hemophilia A, platelet lysates, and commercial
plasma-derived concentrates as sources of FVIII-related antigens. FVIII-producing human umbilical vein cells were processed for
immunocytochemical staining with the use of purified anti-FVIII-antibodies. Immunization of rabbits with PAAG-trapped antigen
induced more potent immune response compared to the standard immunization procedure with Freund’s adjuvant. The lowest
working amount of immune IgG, measured by ELISA, was ~50 ng. Immunoblotting demonstrated that anti-BDDrFVIII antibodies
effectively recognize the whole FVIII molecule (320 kDa), as well as different truncated polypeptides thereof, and are suitable for
immunocytochemical analysis of FVIII-producing cells. An optimized procedure for the production of polyclonal antibodies against
FVIII with the use of PAAG-immobilized BDDrFVIII (moroctocog alpha) was proposed and successfully validated. The produced
antibodies are suitable for detecting and measuring FVIII-related antigens and may have various biomedical applications.
Key words: B-Domain deleted recombinant factor VIII (moroctocog alpha), antibody production, plasma-derived FVIII products,
platelets, hemophilia A

1. Introduction
Factor VIII (FVIII) occupies a pivotal position in the blood
coagulation cascade, and its activation and function are of
central importance in the coagulation events and recent
hemostasis studies. FVIII participates in the intrinsic
pathway of blood coagulation and acts as the cofactor for
factor IXa, which in the presence of Ca2+ and phospholipids
converts factor X into the active proteinase form (Xa). The
human FVIII gene is localized on the long arm of the X
chromosome and consists of 26 exons and introns, for a
total length of 9 kbp in coding sequence. The gene encodes
a large precursor glycoprotein of 2332 amino acid residues
(320 kDa) consisting of six structural domains and three
acidic subdomains, organized in a heavy chain [A1(a1)
A2(a2)B] and a light chain [(a3)A3C1C2] (Figure 1).
* Correspondence: caagca@bingol.edu.tr

FVIII circulates in plasma in relatively low
concentrations (0.1–0.2 µg/mL) and is stabilized by
association with von Willebrand factor (vWF) (Lenting
et al., 1998; Fang et al., 2007). X-chromosome-linked
deficiency of FVIII, resulting in insufficient levels or the
complete absence of FVIII in the bloodstream, is the
primary cause of a severe bleeding disorder widely known
as hemophilia A. It affects approximately 1:5000 male
individuals; however, unlike sufferers of other genetic
diseases, hemophiliacs can be treated successfully by
replacement therapy with intravenous administrations of
exogenous coagulation factor (Chitlur and Young, 2016).
Currently, several recombinant coagulation factor
products are available for use in raising FVIII levels in
patients, though dozens of commercial lyophilized FVIII
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Figure 1. Scheme of the domain structure of the native FVIII molecule (A) and B-domain-truncated recombinant FVIII protein (B).

concentrates produced from cryoprecipitate of pooled
normal human plasma are used as well (Gringeri, 2011).
Although various techniques for further concentrating
and purifying the coagulation factors from donor plasma
were introduced, the problem of control of the quantity
and quality of plasma-derived FVIII products has not been
fully resolved. In screening tests during the manufacturing
process immunoassays are used to quantify or detect the
target antigen related to the disease in patient’s blood.
However, some hemophiliacs (~10%) produce a FVIII
protein that is partially or completely inactive (Lenting et
al., 1998). Therefore, in combination with the functional
(clot-based or chromogenic) tests, quantitative analysis
based on the use of highly specific antibodies to FVIII is
required in order to distinguish factor deficiency from
factor inhibition or defects (Chandler et al., 2003; Lollar,
2003).
The choice and design of an antigen and immunization
procedure are among the most important parameters in the
development of novel immunoassay techniques. Generally,
results of the immunization are affected by many factors,
such as dose, concentration, purity and presentation of
the antigen, choice of adjuvant, time between injections,
and response measurements. Plasma-derived FVIII
molecules are not suitable for specific antisera production
because these products are often contaminated with
variable amounts of vWF, fibrinogen, serum albumin,
and other blood proteins. In addition, after their synthesis
in the liver, the majority of FVIII molecules are cleaved
during expression, resulting in a heterogeneous mixture
of partially cleaved forms of FVIII, and the amounts of
these fragments can vary in cryoprecipitates obtained
from different donors (Butenas et al., 2009). Production of
recombinant immunogenic proteins that are structurally
and immunologically maximally analogous to native target
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molecules is considered to be state-of-the-art industrial
antigen/antibody manufacturing. In our present study, we
used for the first time ReFacto® AF that contains B-domain
deleted recombinant coagulation FVIII (moroctocog
alpha) to produce animal polyclonal antibodies specific
to human FVIII. Moroctocog alpha, which is also referred
to as BDDrFVIII (B-domain deleted rFVIII), represents a
family of third-generation FVIII products, which are free
of vWF and other protein impurities. Moroctocog alpha
is a glycoprotein with an approximate Mm of 170 kDa
consisting of 1438 amino acid residues and has functional
characteristics comparable to those of endogenous FVIII.
It is manufactured by an albumin-free cell culture process
using Chinese hamster ovary (CHO) cells grown in a
chemically defined serum-free cell culture medium that
contains no materials derived from human or animal
sources. It is noteworthy that, in terms of immunogenicity,
BDDrFVIII and plasma-derived native FVIII have very
similar posttranslational modification, including sites of
glycosylation (Recht et al., 2009).
In this study, the primary data on the optimization
of the procedure for polyclonal anti-FVIII-antibody
production by using B-domainless recombinant FVIII
(moroctocog alpha) as an immunogen are reported. We
also describe the main immunochemical characteristics
of the produced antibodies and highlight their potential
biomedical applications.
2. Materials and methods
2.1. Donors and plasma sampling
Venous blood from four men (two healthy male donors
with normal coagulation, aged 22 and 40 years, and two
donors with hemophilia A, aged 33 and 37 years) was
collected into polystyrene pots containing one-ninth
volume of 3.8% trisodium citrate as an anticoagulant.
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Approved consent was obtained from all participants.
Healthy donors were self-reported as free of any oral
medications for at least 10 days; hemophilic donors had
not injected any clotting factors for at least 14 days before
the study. All plasma samples were centrifuged at 3600 × g
for 15 min at 4 °C, divided into aliquots, and frozen at –20
°C until analyzed. Protein concentration in each donor
plasma sample was estimated spectrophotometrically by
the method of Stoscheck (1990).
2.2. Cells
Washed platelets from blood plasma of healthy donors were
obtained by gel-filtration on Sepharose-2B and counted
by optic aggregometry as described previously (Mumaw
et al., 2014). After sedimentation of platelet samples (108
platelets from each donor) by centrifugation at 1500 × g for
5 min at room temperature, supernatants were discarded,
pellets were lysed in nonreducing Laemmli buffer (62.5
mM Tris-HCl, pH 6.8, 1% SDS, 25% glycerol, and 0.01%
bromophenol blue), boiled for 5 min, and frozen at –20 °C
until analyzed.
Human umbilical vein endothelial cells (HUVECs)
(ATCC, USA) were cultured in endothelial culture
medium (ECM; Lonza, Switzerland) containing 5% fetal
bovine serum (FBS) for 2–3 days until they formed a 70%–
80% confluent monolayer. After 1 day of growth in FBSfree ECM, the cells were fixed with 4% paraformaldehyde
for 20 min, permeabilized with cold acetone, and further
processed for immunocytochemical study. FVIIInonproducing human glioblastoma U373 cells (Sigma
Aldrich, USA) were used as a negative control.
2.3. FVIII products
ReFacto® AF (Wyeth Farma S.A., Madrid, Spain)
containing 250 IU of powder of moroctocog alpha was
used as an immunogen. Commercially available plasmaderived FVIII concentrates of Octanate (Octapharma
Pharmazeutika Produktionsges.m.b.H., Vienna, Austria)
and Bioclot A (Biofarma, Bila Tserkva, Ukraine)
were used in this study as sources of FVIII-related
antigens. All products were reconstituted according
to the manufacturers’ instructions. Because of the low
absorbance of purified FVIII due to low aromatic amino
acid content, protein concentrations were measured by
the Bradford method (Bradford, 1976). Immediately after
reconstitution, solutions of FVIII concentrates were mixed
with nonreducing Laemmli sample buffer, boiled, and
stored at –20 °C until analyzed.
2.4. Rabbit immunization schedule
Two groups of male peripubertal New Zealand rabbits
(aged 3–6 months and weighing 1.5–2.2 kg, n = 3) were
selected for the immunization procedure. All procedures
used in this study were in compliance with the National
Institutes of Health guidelines and were approved by the

Institutional Animal Care and Use Committee. Before the
immunization, nonimmune blood was taken from the
ear vein. The rabbits of the first group were injected with
moroctocog alpha in the form of emulsion with complete
Freund’s adjuvant (CFA) (1:1) for a total of 100 µg of
protein per rabbit intracutaneously (i.c.) in 4–5 places
in the paravertebral region. The rabbits were repeatedly
boosted with the half-dose of antigen emulsified with
incomplete Freund’s adjuvant on the 21st day after the first
injection. For immunization of rabbits of the second group,
50 µg of the antigen was separated in a discontinuous 10%
polyacrylamide gel (PAAG) by denaturing electrophoresis
in a Bio-Rad mini-gel chamber. The unstained gel lane
at 170 kDa, according to separation of molecular weight
marker Page Ruler (Page Ruler #26625, MBI Fermentas,
Vilnius, Lithuania), was carefully excised. This antigencontaining PAAG fragment was ground with a pestle in
a mortar with addition of 0.5 mL of phosphate-buffered
saline (PBS), mixed with CFA (10:1 gel suspension and
CFA), and injected i.c. into rabbits. For the repeated
antigen boost, rabbits were injected with a lower amount
of FVIII (25 µg) immobilized in PAAG in accordance with
abovementioned procedure.
Blood from the rabbits of both groups was sampled
on the 5th, 7th, 9th, and 11th days after the last antigen
boost. At each time point, equal volumes of sera from
each of the rabbits were analyzed immunochemically
for antigen titers, using nonimmune sera as a negative
control. Significant levels of immune response were found
in all rabbits; therefore, sera taken from rabbits within the
same group were pooled and stored at –20 °C until further
purification procedures.
2.5. IgG purification
The globulin fraction of immune sera was obtained
by ammonium sulfate (50% saturation solution)
precipitation. After a salting-out procedure, globulin
precipitates were dissolved in 50 mM Tris-HCl buffer, pH
7.4 (TBS), and dialyzed against the same buffer 5 times for
30 min each. The resulting protein solution was loaded on
a protein A-sepharose column (Sigma Aldrich, USA). IgG
molecules specifically bound to affine sorbent were eluted
with 0.1 M glycine buffer, pH 2.8, in accordance with the
manufacturer’s recommendations. Obtained aliquots of
eluted IgG were pooled, and after buffer exchange with 50
mM Tris-HCl-buffered saline (pH 7.4) and a concentration
procedure in Millipore centrifuge tubes (molecular weight
cut-off: 80 kDa), the content of IgG in the final solution
was determined spectrophotometrically using a coefficient
of molar extinction of 13.7 at 280 nm for a 1% (10 mg/mL)
IgG solution (Johnston, 1982). The purity of proteins after
each purification step was monitored electrophoretically
by SDS-PAAG electrophoresis. IgG concentration in the
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final solution was adjusted to 2 mg/mL with TBS, and
sodium azide (0.02%) was added as a preservative. Finally,
the solution was mixed with glycerol (1:1), aliquoted, and
stored at – 20 °C.
2.6. Enzyme-linked immunosorbent analysis (ELISA)
ELISA is a common test for determining antibody titers.
The ELISA titer of antiserum/antibody refers to the
greatest dilution of serum (or minimal concentration of
antigen) that still gives a positive signal. Wells of plastic
96-well microtiter plates (Corning Inc., USA) were
coated with 1 µg of moroctocog alpha dissolved in 100
µL of binding buffer (50 mM carbonate-bicarbonate
buffer, pH 9.6). After overnight incubation at 4 °C, excess
antigen was removed and the plates were washed three
times with PBS containing 0.1% Tween-20 (PBST). In
parallel, dilutions of antisera of rabbits from both groups
as well as purified immune IgG were prepared. Serial
dilutions of antisera in the range of 1:500 to 1:64,000
were prepared, and 4.0–0.03125 µg of IgG was taken.
After blocking in 3% BSA for 1 h at 37 °C, antigen-coated
wells were allowed to react with the appropriately diluted
test sera or IgG for 2 h at room temperature. Wells were
then incubated with the appropriate secondary goat
antirabbit peroxidase-conjugated antibodies diluted at
1:10,000 for 1 h at 37 °C followed by substrate solution
(3,3′,5,5′-tetramethylbenzidine) addition. All reagents,
including the substrate, were added in 100-µL volumes per
well. Between each step, excess reagents were removed by
washing, as described before. Finally, the substrate reaction
was stopped by adding 50 µL of 2.5 N H2SO4 per well. The
absorbance of colored reaction products was measured
at 450 nm (primary test filter) and 630 nm (reference
filter) in a microELISA reader. All samples were tested
in duplicate with each plate containing two positive sera
and one negative reference serum. The final results were
expressed as the mean A (450–630) nm of the duplicates.
2.7. Immunoblotting
Solutions of moroctocog alpha, plasma-derived FVIII
concentrates, human plasma samples, and platelet lysates
were mixed with nonreducing Laemmli sodium dodecyl
sulfate (SDS)-containing sample buffer. The samples of
FVIII products, plasmas, and platelet lysates containing
25, 100, and 50 µg of total protein, respectively, were
loaded onto 10% or 5%–17% gradient PAAG. SDS-PAAG
electrophoresis was then carried out at 150–180 V for 120
min in an electrophoresis buffer containing 25 mM TrisHCl, 0.2 M glycine, and 0.1% SDS.
For immunoblotting, each protein sample was transferred
from gel to a nitrocellulose membrane (GE Healthcare,
Amersham Bioscience, RPN 203D) with 0.45-µm pore
diameter using a Bio-Rad Mini Trans-Blot apparatus at 30
V for 90 min in buffer containing 25 mM Tris-HCl, 0.2 M
glycine, and 25% (v/v) methanol. Before primary antibody
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incubation, the membranes were blocked with 5% (w/v)
nonfat dried milk for 90 min at 37 °C. The membranes
then were incubated with immune sera (1:500) or purified
IgG (3 µg/mL) as primary antibodies at 4 °C overnight.
After incubation, membranes were washed five times with
PBST and probed with secondary antirabbit horseradish
peroxidase (HRP)-conjugated antibodies diluted 1:4000 in
PBST for 90 min at 37 °C. Nonspecifically bound antibodies
were removed by washing five times in PBST for 5 min
each. Specific immunostaining was developed in 0.05%
3,3′-diaminobenzidine solution in 50 mM Tris-HCl (pH
7.4), with addition of 0.01% hydrogen peroxide.
2.8. Immunocytochemistry (ICC)
Fixed and permeabilized HUVECs adhered onto the glass
coverslips were washed with cold PBS three times for 5
min each time. Nonspecific staining was blocked by 60
min of incubation with 5% BSA in PBS at 37 °C. Cells were
then incubated overnight at 4 °C with primary anti-FVIII
IgG in serial dilutions containing 20, 10, 5, 2.5, or 1.25
µg/mL of the IgG for monitoring the optimal regime for
immunostaining. The same procedure was proceeded in
U373 cells (negative control), which were then incubated
with 20 µg/mL anti-FVIII antibodies. U373 cells were
additionally stained for glial fibrillary acidic protein
(GFAP), a glial-specific marker (Goyal et al., 2015). After
that, cells were washed three times with PBST for 5 min and
incubated with secondary antirabbit antibodies conjugated
with green fluorophore fluorescein isothiocyanate (FITC)
(Sigma Aldrich, USA) in 1:500 dilution for 60 min at 37 °C
in the dark. Cells were washed again five times with PBST
for 5 min each time, counterstained with 1 µg/mL blue
fluorescent dye Hoechst-33342 (Sigma Aldrich, USA) for
5 min at room temperature to label cell nuclei, and finally
rinsed in PBS and observed under an LSM 510 confocal
laser scanning microscope (Zeiss, Germany). A laser with
wavelength of 488 or 405 nm was used for FITC or Hoechst
excitation, respectively, and the emission was detected by
the channel of >505 nm for FITC and 420–480 nm for
Hoechst. HUVECs treated without primary antibodies
were used as a control of nonspecific secondary antibody
binding. Afterwards, laser power and the detector settings
were kept constant to maintain consistency in the data
collection system. For visualization studies, 10–20 cells for
each condition were examined in random ﬁelds in at least
three experiments. Images were collected and analyzed
using Zeiss ZEN 2009 Light Edition software.
2.9. Data analysis
The results of immunoblotting and immunocytochemistry
were qualitatively reported and statistical analysis was
not conducted. Differences between mean optical density
intensities, reflecting antigen-antibody binding in ELISA,
were calculated by one-way ANOVA followed by Tukey’s
post hoc test. P < 0.05 was considered statistically significant.
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3. Results
3.1. Isolations and purification of IgG
The protein spectra of the serum and the fractions yielded
by different stages of purification are presented in Figure 2.
SDS-PAGE analysis of affinity-isolated IgG showed a single
major band at 150 kDa and the final antibody product has
high electrophoretic purity.
3.2. ELISA titers of anti-BDDrFVIII antibodies
As seen in Figure 3, serological analysis (ELISA) of
immune sera indicates that rabbits injected with PAAGimmobilized BDDrFVIII had 4-fold higher antibody
titers than did the rabbits immunized in accordance
with conventional procedure (1/12,000 and 1/3000,
respectively). Titer evaluation of purified IgG showed a
statistically significant difference between the signal from
immune IgG and the negative control threshold baseline at
the concentration of ~50 ng.
3.3. Characteristics of anti-BDDrFVIII specificity to
FVIII-related antigens
The specificities of antisera obtained from rabbits
immunized with gel-entrapped moroctocog were found
to differ from those obtained from animals injected with
antigen in the form of emulsion with adjuvant (Figure 4).
As expected, antisera taken from both groups of rabbits
reacted with the moroctocog alpha, which they produced

Figure 2. Electrophoresis (8% PAAG) of immune serum – 100
µg of protein (1), globulin fraction – 50 µg of protein (2), eluate
from protein A-sepharose – 2.5 µg of protein (3) and 5.0 µg of
protein (4).

against (170 kDa) FVIII-related polypeptides in plasmaderived concentrates and human serum. With that,
antisera of rabbits immunized with PAAG-immobilized
BDDrFVIII appeared to recognize the intact native FVIII

Figure 3. ELISA absorbance profiles of immune sera of rabbits injected with PAAG-immobilized or BDDrFVIII in the form of emulsion
with Freund’s adjuvant. Inset: results of ELISA test for titer evaluation of purified IgG.
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Figure 4. Immunoblotting of FVIII-related antigens (1 – moroctocog alpha – 15 µg protein; 2 – Bioclot – 25 µg; 3 – Octanate – 25 µg;
4 – serum of a healthy donor – 100 µg) with the use of immune sera as primary antibodies (dilution 1:500).

molecule (320 kDa) in the samples of Bioclot and Octanate
concentrates as well as whole human serum. However,
antisera obtained from conventionally immunized rabbits
were not capable of such detection. In addition, antibodies
from that group of rabbits demonstrated weak reactivity
toward the 170-kDa polypeptide in Octanate concentrate
and the 220-kDa polypeptide in Bioclot concentrate. Thus,
due to higher titers and better capability to recognize a
wider spectrum of epitopes, the IgG fractions purified from
PAAG-BDDrFVIII-injected rabbits were further used as
primary antibodies in the immunoblotting analysis for
the antigen detection in sera of individuals with normal
clotting, people with hemophilia A, and washed human
platelets (Figure 5).
We did not perform quantitative analysis of
immunoblot results, but it is obviously seen that densities
of immunostaining of the major polypeptide of 320 kDa
as well as FVIII-related polypeptides with lower molecular
masses are much less abundant in the samples of hemophilia
A patients than in the healthy controls. It is of interest that
there is no such pronounced difference between these two
types of serum samples in the immunostaining of the 40kDa polypeptide.
Since some literature data previously reported that
human platelets store FVIII in their α-granules along with
FVW (Obergfell et al., 2006), our next step was to check
if produced antibodies could be suitable for detecting
FVIII in platelets, which might have clinical implications.
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Surprisingly, distinct polypeptide compositions of
FVIII-related antigens were shown in lysates of washed
platelets obtained from healthy volunteers. In one case,
in addition to the vast number of minor immunoreactive
bands, FVIII-related antigens were represented by two
major polypeptides migrated as 320 and 55 kDa. In the
second case, we failed to demonstrate a platelet-related
polypeptide corresponding to native FVIII (320 kDa),
whereas another major immunoreactive band of about 70
kDa was observed.
3.4. HUVEC immunolabeling with anti-BDDrFVIII
antibodies
It has been previously established that FVIII synthesis is
observed only in endothelial cells and thus can be used
as the marker of those cells (Hollestelle et al., 2001).
According to this, we performed an immunofluorescence
assay of HUVECs as potential FVIII producers to
detect such production. Five different concentrations
of anti-FVIII IgG were chosen to design a novel
immunofluorescence assay to find the optimal antibody
concentration for labeling antigen. Fluorescence
microscopy confirmed the presence of FVIII-positive
cells, and specific immunostaining was evenly localized
throughout their cytosols (Figures 6A–6H). Translated
into practical terms, due to the high sensitivity of the
method used, primary antibody concentrations must be
reduced to obtain optimal staining. Thus, the optimum
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Figure 5. Immunoblotting of FVIII-related antigens (1 – healthy volunteer #1; 2 –
healthy volunteer #2; 3 – person with hemophilia A #1; 4 – person with hemophilia
A #2; 5 – platelet lysate #1; 6 – platelet lysate #2) with the use of IgG (3 µg/mL) as
primary antibodies.

antibody concentration should provide the maximum
difference in positive cell numbers and signal intensities
between contrasting cell populations.
Our study demonstrated the increase in both the quantity
of positively stained cells and specific signal intensities with
the increase in antibody concentration. It is noteworthy
that, at an IgG concentration of 10 µg/mL, all cells stained
positively. Therefore, the appropriate concentration of
purified immune IgG, which is recommended to be used
for ICC, can be between 5 and 10 µg/mL. In contrast, no
significant signals were obtained in the cases of absorption
controls (HUVECs with the primary antibodies omitted
and U373 incubated with 20 µg/mL anti-FVIII IgG, Figures
6A and 6H, respectively). Specific GFAP staining in U373
cells indicates that the procedure ran well (see Figure 6H,
insert). The absence of anti-FVIII-fluorescence visualization
in these samples is important proof of primary antibody
specificity and the lack of nonspecific binding for secondary
conjugated antibodies.
4. Discussion
In this study, we attempted to improve antibody production
against human FVIII by means of immunization of
rabbits with gel-immobilized BDDrFVIII (moroctocog
alpha) in the presence of a minor amount of Freund’s
adjuvant. The main benefit of the proposed method is

the dramatic enhancement of the immune response,
since polyacrylamide helps to retain the antigen in
animals and so acts as an adjuvant. In addition, in the
presence of a denaturing agent, SDS, protein antigens
are partially unfolded and become more accessible for
immunocompetent cells to yield antibodies capable of
recognizing a wider spectrum of epitopes within the
same antigen molecule. Therefore, the use of the protein
entrapped in the gel band (without elution) is also helpful
when only small amounts of protein are available, and
thus the proposed method is beneficial compared to the
conventional immunization techniques, allowing the use
of lower quantities of both antigen and adjuvant (Amero
et al., 1988). Previously, several research groups described
the procedure of anti-FVIII-antibodies generation. For
example, Sohrabi et al. (2011) used Al(OH)3 as an adjuvant
for rabbit immunization with FVIII. The authors shot
4000 µg of FVIII per each injection and obtained antibody
titers between 1/1000 and 1/10,000, lower than the
levels obtained with the use of much smaller amounts of
antigen immobilized in gel, as described above. Therefore,
according to our optimized protocol for antibody
production enabling the increase in the immunogenicity
of a recombinant analog of human FVIII, we were able to
provide high antibody titers using minimal quantities of
both antigen and adjuvant.
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Figure 6. FVIII immunofluorescence assay of human umbilical vein endothelial cells (HUVECs) (green – FVIII; blue – nuclei). Content
of immune Ig G, µg/mL: 0 (A), 1.25 (B), 2.5 (C), 5 (D), 10 (E), 20 (F and G). H – Negative control (glioblastoma U373 cell line): 20 µg/
mL of immune IgG (inset: immunostaining for GFAP, the specific marker of glial cells).
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ELISA and western blot were used in this study
to determine antibody titers and specificity, and an
immunostaining assay was performed in order to provide
confirmation of the results. It is known that mature 320kDa FVIII consists of 2332 amino acid residues, which
are arranged in a discrete domain structure: A1-A2-BA3-C1-C2. The light chain has a molecular weight of
80 kDa and is made up of the domains A3-C1-C2. The
heavy chain is composed of the domains A1-A2-B and
has a more heterogeneous composition with molecular
weights varying from 90 to 200 kDa. Every domain plays
a physiological role throughout the life cycle of FVIII,
from biosynthesis to clearance. A particular case is the
908-amino acid residue B-domain, which does not seem
to be required for FVIII clotting activity but is important
for processing, intracellular transport, and secretion of
FVIII protein. The glycosylation process may impart some
discrepancy between the observed molecular weight of
FVIII following its purification and the values calculated
based upon its primary structure. The amino-terminal
signal peptide is removed upon translocation of FVIII into
the endoplasmic reticulum, and the native FVIII molecule
is then cleaved within the B-domain during secretion
of the FVIII molecule from the cell. This results in the
release of a heterodimer comprising a 200-kDa heavy
chain and an 80-kDa light chain, the association of which
is metal ion-dependent. In addition to intact FVIII heavy
and light chains, their proteolytic products can also be
formed, such as A1A2. Activation of FVIII results from
limited proteolysis catalyzed by thrombin or factor Xa,
which binds the FVIII substrate over extended interactive
surfaces. The proteases efficiently cleave FVIII at three
sites, two within the heavy chain and one within the light
chain, resulting in the alteration of its covalent structure
and conformation and yielding the active cofactor, factor
VIIIa. Thus, limited proteolysis of the B-chain creates
heterogeneous population of active FVIII forms of varied
molecular weights (Lenting et al., 1998; Fang et al., 2007;
Mazurkiewicz-Pisarek et al., 2016). Figures 4 and 5
represent the heterogeneity of FVIII chains circulating in
human plasma and indicate that antibodies produced in
our experiment are suitable for quantitative analysis, as
well as characterization of the polypeptide spectrum of
this clotting factor. It is generally accepted that decreased
levels or malfunctions of FVIII result in hemophilia A,
a bleeding disorder, while elevated FVIII activity is a
risk factor for thrombosis. Combined functional and
immunochemical assays of FVIII have clinical importance
for diagnostics of hemostasis disorders related to clotting
factor abnormalities (Chandler et al., 2003).
Recently, a recombinant truncated form of factor
VIII, moroctocog alpha, lacking most of the B-domain,
has been developed and characterized, and it was

demonstrated to have equal clinical efficiency (Recht et al.,
2009). This concentrate does not contain human albumin
or other protein impurities. Moroctocog alpha has high
physiological activity, shares structural/antigen features
with the native protein, and is produced in high purity
(Windyga et al., 2010; Mazurkiewicz-Pisarek et al., 2016).
For these reasons, we used it as an antigen for production of
antibodies, which were expected to recognize native FVIIIrelated proteins. Indeed, moroctocog alpha appeared to be
suitable for the production of highly specific and affine
antibodies capable of recognizing native FVIII molecules
and their truncated products. In addition, the use of a gelentrapped antigen is highly recommended for obtaining
high titer antibodies.
Despite the increased availability and quality of
commercial recombinant FVIII analogs and their extensive
use in clinical practice, plasma-derived concentrates of
FVIII for the replacement therapy of hemophilia A are
still widely available. Accurate assessment of the quantity
and quality of FVIII is crucial for successful outcomes
in hemophilia patients undergoing FVIII replacement
therapy. One of the major concerns about these FVIII
products is the high variation and inconsistency of
the target protein concentration in the product, which
greatly contributes to the differences in FVIII-specific
activity from batch to batch. Also, a particular problem
associated with FVIII preparations is the presence of FVIII
degradation products (Clifton et al., 2009). Degradation
products can interfere with FVIII function by interacting
with substrate proteins, reducing the efficiency of FVIII
activation by the substrates. Use of excess FVIII in patients
is also undesirable as it can enhance the production
of neutralizing FVIII-specific antibodies (Lindgren
et al., 2002). Available bioassays for FVIII reflect only
the concentration of fully functional FVIII; however, if
FVIII preparations contain degraded or inactive FVIII,
such products are not detectable by bioassays. Sensitive
immunoassays, such as the immunoblotting exemplified
in our study, have enhanced ability to precisely assess the
quality of FVIII concentrates compared to conventional
routine tests.
Application of immunochemical techniques based
on the use of highly specific and affine antibodies would
help to uncover the cellular origin of FVIII synthesis in
the body. Paradoxically, the question of where FVIII is
produced is still incompletely answered. It is discussed
whether hepatocytes or sinusoidal endothelial and Kupffer
cells in the liver are the major site of FVIII expression.
However, production of FVIII was demonstrated in
endothelial cells located outside the liver throughout the
body (Hollestelle et al., 2001). For example, Jacquemin
et al. (2006) showed that FVIII is synthesized in the lung
microvascular endothelium. The greatest challenge in the
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development of immunocytochemistry techniques is to
determine if the antibody has binding activity and, if so,
whether that activity truly identifies the antigen against
which the antibody was generated. In the present study,
we provide experimental evidence that anti-BDDrFVIII
antibodies effectively label FVIII-producing cells that,
together with other immunochemical methods, serves as
additional evidence for antibody specificity. Our results
are in agreement with the earlier data obtained by Turner
and Moake (2015). They showed FVIII to be normally
synthesized in HUVECs, stored together with vWF in
Weibel–Palade bodies, and secreted in response to cell
stimulation. We can assume that novel, more sensitive
immunoassay procedures will provide new evidence about
the origin of this coagulation factor and its circulation in
the body.
It is absolutely critical for thorough antibody
characterization to check the specificity of antibodies used
for ICC assays. In our study, additional evidence for antiFVIII-antibody specificity may be the absence of specific
immunostaining for the U373 cell line, which are FVIIInonsynthesizing human glioblastoma cells. It is of interest
that, in tumors, glioma cells have the ability to interact
with endotheliocytes through the secretion of vascular
endothelial growth factor (VEGF), and the angiogenesis
rate (capillary number/sprouting, vessel density) can be
estimated by FVIII assay (Ouafik et al., 2002).
Among FVIII-producing cells of nonendothelial
nature, platelets attract special attention of the researchers.
The evidence that FVIII is present in mammal platelets
is still controversial. Extensive studies on human,
canine, and mouse platelets failed to demonstrate FVIII
protein, and FVIII staining is only positive when platelet/
megakaryocyte expression is driven by transfection or
transduction (Shi et al., 2003). Other studies demonstrated

that FVIII could be ectopically expressed during
megakaryopoiesis and stored in α-granules (Yarovoi et
al., 2003). Moreover, activated FVIII bound to platelet
surfaces plays the role of a cofactor that assembles on the
membrane of activated platelets during the amplification
and propagation phases. In the study of Obergfell et
al. (2006), FVIII was reported to be a positive regulator
of platelet function since it binds to platelets with high
efficacy and activates αIIbβ3 receptors, thus inducing
platelet spreading and aggregation. FVIII-induced platelet
activation is hypothesized to play a causative role in vessel
thrombus formation in individuals with high FVIII levels.
It is possible that platelet FVIII expression may then be
a viable strategy for hemophilia A therapy. On the other
hand, deficiency of FVIII/VWF activity is responsible for
the failure of the platelets to participate fully in the initial
stages of hemostasis (Montgomery and Shi, 2012). As
bleeding disorders and thrombotic events are the results of
insufficient function of platelets or their hyperactivation,
respectively, further studies of the interaction between
platelets and FVIII and its processing on the platelet
surface may provide supplementary clinical information
for patients with hemostasis pathologies.
In conclusion, it was established for the first time that
human recombinant B-domainless FVIII (moroctocog
alpha) is suitable for the production of highly specific and
affine polyclonal antibodies, capable of recognizing native
whole FVIII molecules, as well as its truncated products.
An improved protocol for rabbit immunization was
proposed and successfully validated. The results obtained
could be useful for the development of novel protocols
of sensitive immunoassay techniques for clarifying
intracellular expression and localization of FVIII and
other biomedical applications.
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